Zynex (NASDAQ:ZYXI) Releases Q4 Earnings Guidance

Zynex (NASDAQ:ZYXI) updated its fourth quarter earnings guidance on Thursday. The company provided earnings per share guidance of at least $0.09 for the period, compared to the consensus earnings per share estimate of $0.10. The company issued revenue guidance of at least $53.6 million, compared to the consensus revenue estimate of $53.30 million. Zynex also updated its FY 2024 guidance to 0.200- EPS.

Zynex Stock Up 6.2 %

Zynex stock traded up $0.53 during midday trading on Friday, hitting $9.12. 264,477 shares of the company were exchanged, compared to its average volume of 173,892. The company has a market cap of $289.47 million, a PE ratio of 50.67 and a beta of 0.54. Zynex has a fifty-two week low of $7.04 and a fifty-two week high of $13.77. The company’s fifty day moving average price is $8.01 and its 200-day moving average price is $9.20. The company has a debt-to-equity ratio of 1.79, a current ratio of 4.06 and a quick ratio of 3.22.

Zynex (NASDAQ:ZYXI) last posted its quarterly earnings data on Thursday, October 24th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. Zynex had a net margin of 3.12% and a return on equity of 14.15%. The company had revenue of $49.97 million during the quarter, compared to analysts’ expectations of $50.83 million. During the same period in the prior year, the company posted $0.10 EPS. The firm’s revenue for the quarter was up .1% on a year-over-year basis. On average, research analysts predict that Zynex will post 0.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ZYXI. Royal Bank of Canada decreased their target price on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. HC Wainwright lifted their price objective on shares of Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a report on Friday.

Insiders Place Their Bets

In related news, Director Joshua R. Disbrow acquired 7,000 shares of the stock in a transaction that occurred on Monday, July 29th. The shares were acquired at an average price of $8.32 per share, for a total transaction of $58,240.00. Following the completion of the purchase, the director now directly owns 72,000 shares of the company’s stock, valued at $599,040. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, COO Anna Lucsok sold 8,083 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $8.03, for a total transaction of $64,906.49. Following the completion of the sale, the chief operating officer now directly owns 16,980 shares in the company, valued at approximately $136,349.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Joshua R. Disbrow purchased 7,000 shares of the company’s stock in a transaction on Monday, July 29th. The stock was bought at an average cost of $8.32 per share, for a total transaction of $58,240.00. Following the acquisition, the director now directly owns 72,000 shares of the company’s stock, valued at $599,040. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 52.13% of the stock is currently owned by insiders.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.